Histone deacetylase explained

Histone deacetylase
Ec Number:	3.5.1.98
Cas Number:	9076-57-7
Go Code:	0046970

Histone deacetylases (HDAC) are a class of enzymes that remove acetyl groups (O=C-CH₃) from an ε-N-acetyl lysine amino acid on both histone and non-histone proteins.^[1] HDACs allow histones to wrap the DNA more tightly.^[2] This is important because DNA is wrapped around histones, and DNA expression is regulated by acetylation and de-acetylation. HDAC's action is opposite to that of histone acetyltransferase. HDAC proteins are now also called lysine deacetylases (KDAC), to describe their function rather than their target, which also includes non-histone proteins.^[3] In general, they suppress gene expression.^[4]

HDAC super family

Together with the acetylpolyamine amidohydrolases and the acetoin utilization proteins, the histone deacetylases form an ancient protein superfamily known as the histone deacetylase superfamily.^[5]

Classes of HDACs in higher eukaryotes

HDACs, are classified in four classes depending on sequence homology to the yeast original enzymes and domain organization:^[6]

HDAC classification in higher eukaryotes

Class	Members	Catalytic sites	Subcellular localization	Tissue distribution	Substrates	Binding partners	Knockout phenotype
I		1	Nucleus	Ubiquitous		–	Embryonic lethal, increased histone acetylation, increase in p21 and p27
		1	Nucleus	Ubiquitous		–	Cardiac defect
		1	Nucleus	Ubiquitous		NCOR1^[7]	–
		1	Nucleus/cytoplasm	Ubiquitous?	–		–
IIA		1	Nucleus / cytoplasm	heart, skeletal muscle, brain			Defects in chondrocyte differentiation
		1	Nucleus / cytoplasm	heart, skeletal muscle, brain			Cardiac defect
		1	Nucleus / cytoplasm / mitochondria	heart, skeletal muscle, pancreas, placenta			Maintenance of vascular integrity, increase in MMP10
		1	Nucleus / cytoplasm	brain, skeletal muscle	–		Cardiac defect
IIB		2	Mostly cytoplasm	heart, liver, kidney, placenta			–
		1	Mostly cytoplasm	liver, spleen, kidney	–	–	–
III	sirtuins in mammals (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7)	–	–	–	–	–	–
	Sir2 in the yeast S. cerevisiae	–	–	–	–	–	–
IV		2	Nucleus / cytoplasm	brain, heart, skeletal muscle, kidney	–	–	–

HDAC (except class III) contain zinc and are known as Zn²⁺-dependent histone deacetylases.^[8] They feature a classical arginase fold and are structurally and mechanistically distinct from sirtuins (class III), which fold into a Rossmann architecture and are NAD⁺ dependent.^[9]

Subtypes

HDAC proteins are grouped into four classes (see above) based on function and DNA sequence similarity. Class I, II and IV are considered "classical" HDACs whose activities are inhibited by trichostatin A (TSA) and have a zinc dependent active site, whereas Class III enzymes are a family of NAD⁺-dependent proteins known as sirtuins and are not affected by TSA.^[10] Homologues to these three groups are found in yeast having the names: reduced potassium dependency 3 (Rpd3), which corresponds to Class I; histone deacetylase 1 (hda1), corresponding to Class II; and silent information regulator 2 (Sir2), corresponding to Class III. Class IV contains just one isoform (HDAC11), which is not highly homologous with either Rpd3 or hda1 yeast enzymes,^[11] and therefore HDAC11 is assigned to its own class. The Class III enzymes are considered a separate type of enzyme and have a different mechanism of action; these enzymes are NAD⁺-dependent, whereas HDACs in other classes require Zn²⁺ as a cofactor.^[12]

Evolution

HDACs are conserved across evolution, showing orthologs in all eukaryotes and even in Archaea. All upper eukaryotes, including vertebrates, plants and arthropods, possess at least one HDAC per class, while most vertebrates carry the 11 canonical HDACs, with the exception of bone fish, which lack HDAC2 but appears to have an extra copy of HDAC11, dubbed HDAC12. Plants carry additional HDACs compared to animals, putatively to carry out the more complex transcriptional regulation required by these sessile organisms. HDACs appear to be deriving from an ancestral acetyl-binding domain, as HDAC homologs have been found in bacteria in the form of Acetoin utilization proteins (AcuC) proteins.

Subcellular distribution

Within the Class I HDACs, HDAC1, 2, and 3 are found primarily in the nucleus, whereas HDAC8 is found in both the nucleus and the cytoplasm, and is also membrane-associated. Class II HDACs (HDAC4, 5, 6, 7 9, and 10) are able to shuttle in and out of the nucleus, depending on different signals.^{[13] [14]}

HDAC6 is a cytoplasmic, microtubule-associated enzyme. HDAC6 deacetylates tubulin, Hsp90, and cortactin, and forms complexes with other partner proteins, and is, therefore, involved in a variety of biological processes.^[15]

Function

Histone modification

Histone tails are normally positively charged due to amine groups present on their lysine and arginine amino acids. These positive charges help the histone tails to interact with and bind to the negatively charged phosphate groups on the DNA backbone. Acetylation, which occurs normally in a cell, neutralizes the positive charges on the histone by changing amines into amides and decreases the ability of the histones to bind to DNA. This decreased binding allows chromatin expansion, permitting genetic transcription to take place. Histone deacetylases remove those acetyl groups, increasing the positive charge of histone tails and encouraging high-affinity binding between the histones and DNA backbone. The increased DNA binding condenses DNA structure, preventing transcription.

Histone deacetylase is involved in a series of pathways within the living system. According to the Kyoto Encyclopedia of Genes and Genomes (KEGG), these are:

• Environmental information processing; signal transduction; notch signaling pathway PATH:ko04330
• Cellular processes; cell growth and death; cell cycle PATH:ko04110
• Human diseases; cancers; chronic myeloid leukemia PATH:ko05220

Histone acetylation plays an important role in the regulation of gene expression. Hyperacetylated chromatin is transcriptionally active, and hypoacetylated chromatin is silent. A study on mice found that a specific subset of mouse genes (7%) was deregulated in the absence of HDAC1.^[16] Their study also found a regulatory crosstalk between HDAC1 and HDAC2 and suggest a novel function for HDAC1 as a transcriptional coactivator. HDAC1 expression was found to be increased in the prefrontal cortex of schizophrenia subjects,^[17] negatively correlating with the expression of GAD67 mRNA.

Non-histone effects

It is a mistake to regard HDACs solely in the context of regulating gene transcription by modifying histones and chromatin structure, although that appears to be the predominant function. The function, activity, and stability of proteins can be controlled by post-translational modifications. Protein phosphorylation is perhaps the most widely studied and understood modification in which certain amino acid residues are phosphorylated by the action of protein kinases or dephosphorylated by the action of phosphatases. The acetylation of lysine residues is emerging as an analogous mechanism, in which non-histone proteins are acted on by acetylases and deacetylases.^[18] It is in this context that HDACs are being found to interact with a variety of non-histone proteins—some of these are transcription factors and co-regulators, some are not. Note the following four examples:

• HDAC6 is associated with aggresomes. Misfolded protein aggregates are tagged by ubiquitination and removed from the cytoplasm by dynein motors via the microtubule network to an organelle termed the aggresome. HDAC 6 binds polyubiquitinated misfolded proteins and links to dynein motors, thereby allowing the misfolded protein cargo to be physically transported to chaperones and proteasomes for subsequent destruction.^[19] HDAC6 is important regulator of HSP90 function and its inhibitor proposed to treat metabolic disorders.^[20]
• PTEN is an important phosphatase involved in cell signaling via phosphoinositols and the AKT/PI3 kinase pathway. PTEN is subject to complex regulatory control via phosphorylation, ubiquitination, oxidation and acetylation. Acetylation of PTEN by the histone acetyltransferase p300/CBP-associated factor (PCAF) can repress its activity; on the converse, deacetylation of PTEN by SIRT1 deacetylase and, by HDAC1, can stimulate its activity.^{[21] [22]}
• APE1/Ref-1 (APEX1) is a multifunctional protein possessing both DNA repair activity (on abasic and single-strand break sites) and transcriptional regulatory activity associated with oxidative stress. APE1/Ref-1 is acetylated by PCAF; on the converse, it is stably associated with and deacetylated by Class I HDACs. The acetylation state of APE1/Ref-1 does not appear to affect its DNA repair activity, but it does regulate its transcriptional activity such as its ability to bind to the PTH promoter and initiate transcription of the parathyroid hormone gene.^{[23] [24]}
• NF-κB is a key transcription factor and effector molecule involved in responses to cell stress, consisting of a p50/p65 heterodimer. The p65 subunit is controlled by acetylation via PCAF and by deacetylation via HDAC3 and HDAC6.^[25]

These are just some examples of constantly emerging non-histone, non-chromatin roles for HDACs.

HDAC inhibitors

See main article: Histone deacetylase inhibitor.

Histone deacetylase inhibitors (HDIs) have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics, for example, valproic acid. In more recent times, HDIs are being studied as a mitigator or treatment for neurodegenerative diseases.^{[26] [27] [28]} Also in recent years, there has been an effort to develop HDIs for cancer therapy.^{[29] [30]} Vorinostat (SAHA) was FDA approved in 2006 for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) that have failed previous treatments. A second HDI, Istodax (romidepsin), was approved in 2009 for patients with CTCL. The exact mechanisms by which the compounds may work are unclear, but epigenetic pathways are proposed.^[31] In addition, a clinical trial is studying valproic acid effects on the latent pools of HIV in infected persons.^[32] HDIs are currently being investigated as chemosensitizers for cytotoxic chemotherapy or radiation therapy, or in association with DNA methylation inhibitors based on in vitro synergy.^[33] Isoform selective HDIs which can aid in elucidating role of individual HDAC isoforms have been developed.^{[34] [35] [36] [28]}

HDAC inhibitors have effects on non-histone proteins that are related to acetylation. HDIs can alter the degree of acetylation of these molecules and, therefore, increase or repress their activity. For the four examples given above (see Function) on HDACs acting on non-histone proteins, in each of those instances the HDAC inhibitor Trichostatin A (TSA) blocks the effect. HDIs have been shown to alter the activity of many transcription factors, including ACTR, cMyb, E2F1, EKLF, FEN 1, GATA, HNF-4, HSP90, Ku70, NFκB, PCNA, p53, RB, Runx, SF1 Sp3, STAT, TFIIE, TCF, and YY1.^{[37] [38]}

The ketone body β-hydroxybutyrate has been shown in mice to increase gene expression of FOXO3a by histone deacetylase inhibition.^[39]

Histone deacetylase inhibitors may modulate the latency of some viruses, resulting in reactivation.^[40] This has been shown to occur, for instance, with a latent human herpesvirus-6 infection.

Histone deacetylase inhibitors have shown activity against certain Plasmodium species and stages which may indicate they have potential in malaria treatment. It has been shown that HDIs accumulate acetylated histone H3K9/H3K14, a downstream target of class I HDACs.^[41]

See also

• Histone acetyltransferase (HAT)
• Histone deacetylase inhibitor
• Histone methyltransferase (HMT)
• Histone-modifying enzymes
• RNA polymerase control by chromatin structure

External links

• • Animation at Merck

Notes and References

1. Seto . Edward . Yoshida . Minoru . 2014-04-01 . Erasers of histone acetylation: the histone deacetylase enzymes . Cold Spring Harbor Perspectives in Biology . 6 . 4 . a018713 . 10.1101/cshperspect.a018713 . 1943-0264 . 3970420 . 24691964.
2. Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM . Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability . Genes . 11 . 5 . 556–604 . May 2020 . 32429325 . 7288346 . 10.3390/genes11050556 . free .
3. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M . 6 . Lysine acetylation targets protein complexes and co-regulates major cellular functions . Science . 325 . 5942 . 834–840 . August 2009 . 19608861 . 10.1126/science.1175371 . 2009Sci...325..834C . 206520776 . free .
4. 2015. 10.1615/critrevoncog.2015012997. Hong Ping. Yu Tina. Ting C. 1–2. Crit Rev Oncog. Chen. Zhao. Zhao. 35–47. 25746103. Histone Deacetylases and Mechanisms of Regulation of Gene Expression (Histone deacetylases in cancer). 20. 4809735 .
5. Leipe DD, Landsman D . Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily . Nucleic Acids Research . 25 . 18 . 3693–3697 . September 1997 . 9278492 . 146955 . 10.1093/nar/25.18.3693 .
6. Dokmanovic M, Clarke C, Marks PA . Histone deacetylase inhibitors: overview and perspectives . Molecular Cancer Research . 5 . 10 . 981–989 . October 2007 . 17951399 . 10.1158/1541-7786.MCR-07-0324 .
7. You SH, Lim HW, Sun Z, Broache M, Won KJ, Lazar MA . Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo . Nature Structural & Molecular Biology . 20 . 2 . 182–187 . February 2013 . 23292142 . 3565028 . 10.1038/nsmb.2476 .
8. Marks PA, Xu WS . Histone deacetylase inhibitors: Potential in cancer therapy . Journal of Cellular Biochemistry . 107 . 4 . 600–608 . July 2009 . 19459166 . 2766855 . 10.1002/jcb.22185 .
9. Bürger M, Chory J . Structural and chemical biology of deacetylases for carbohydrates, proteins, small molecules and histones . Communications Biology . 1 . 217 . 2018 . 30534609 . 6281622 . 10.1038/s42003-018-0214-4 .
10. Imai S, Armstrong CM, Kaeberlein M, Guarente L . Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase . Nature . 403 . 6771 . 795–800 . February 2000 . 10693811 . 10.1038/35001622 . 2000Natur.403..795I . 2967911 .
11. Yang XJ, Seto E . The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men . Nature Reviews. Molecular Cell Biology . 9 . 3 . 206–218 . March 2008 . 18292778 . 2667380 . 10.1038/nrm2346 .
12. Barneda-Zahonero B, Parra M . Histone deacetylases and cancer . Molecular Oncology . 6 . 6 . 579–589 . December 2012 . 22963873 . 5528343 . 10.1016/j.molonc.2012.07.003 .
13. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB . Histone deacetylases (HDACs): characterization of the classical HDAC family . The Biochemical Journal . 370 . Pt 3 . 737–749 . March 2003 . 12429021 . 1223209 . 10.1042/BJ20021321 .
14. Longworth MS, Laimins LA . Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src . Oncogene . 25 . 32 . 4495–4500 . July 2006 . 16532030 . 10.1038/sj.onc.1209473 .
15. Valenzuela-Fernández A, Cabrero JR, Serrador JM, Sánchez-Madrid F . HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions . Trends in Cell Biology . 18 . 6 . 291–297 . June 2008 . 18472263 . 10.1016/j.tcb.2008.04.003 .
16. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, Egger G, Grausenburger R, Schweifer N, Chiocca S, Decker T, Seiser C . 6 . Negative and positive regulation of gene expression by mouse histone deacetylase 1 . Molecular and Cellular Biology . 26 . 21 . 7913–7928 . November 2006 . 16940178 . 1636735 . 10.1128/MCB.01220-06 .
17. Sharma RP, Grayson DR, Gavin DP . Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection . Schizophrenia Research . 98 . 1–3 . 111–117 . January 2008 . 17961987 . 2254186 . 10.1016/j.schres.2007.09.020 .
18. Glozak MA, Sengupta N, Zhang X, Seto E . Acetylation and deacetylation of non-histone proteins . Gene . 363 . 15–23 . December 2005 . 16289629 . 10.1016/j.gene.2005.09.010 .
19. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM . Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation . Cancer Research . 68 . 8 . 2557–2560 . April 2008 . 18413721 . 10.1158/0008-5472.CAN-07-5989 . free .
20. Mahla RS . Comment on: Winkler et al. Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes 2012;61:513-523 . Diabetes . 61 . 7 . e10; author reply e11 . July 2012 . 22723278 . 3379673 . 10.2337/db12-0323 .
21. Ikenoue T, Inoki K, Zhao B, Guan KL . PTEN acetylation modulates its interaction with PDZ domain . Cancer Research . 68 . 17 . 6908–6912 . September 2008 . 18757404 . 10.1158/0008-5472.CAN-08-1107 . free .
22. Yao XH, Nyomba BL . Hepatic insulin resistance induced by prenatal alcohol exposure is associated with reduced PTEN and TRB3 acetylation in adult rat offspring . American Journal of Physiology. Regulatory, Integrative and Comparative Physiology . 294 . 6 . R1797–R1806 . June 2008 . 18385463 . 10.1152/ajpregu.00804.2007 .
23. Bhakat KK, Izumi T, Yang SH, Hazra TK, Mitra S . Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene . The EMBO Journal . 22 . 23 . 6299–6309 . December 2003 . 14633989 . 291836 . 10.1093/emboj/cdg595 .
24. Fantini D, Vascotto C, Deganuto M, Bivi N, Gustincich S, Marcon G, Quadrifoglio F, Damante G, Bhakat KK, Mitra S, Tell G . 6 . APE1/Ref-1 regulates PTEN expression mediated by Egr-1 . Free Radical Research . 42 . 1 . 20–29 . January 2008 . 18324520 . 2677450 . 10.1080/10715760701765616 .
25. Hasselgren PO . Ubiquitination, phosphorylation, and acetylation--triple threat in muscle wasting . Journal of Cellular Physiology . 213 . 3 . 679–689 . December 2007 . 17657723 . 10.1002/jcp.21190 . free .
26. Hahnen E, Hauke J, Tränkle C, Eyüpoglu IY, Wirth B, Blümcke I . Histone deacetylase inhibitors: possible implications for neurodegenerative disorders . Expert Opinion on Investigational Drugs . 17 . 2 . 169–184 . February 2008 . 18230051 . 10.1517/13543784.17.2.169 . 14344174 .
27. Web site: Scientists 'reverse' memory loss . 2007-07-08 . BBC News . 2007-04-29.
28. Geurs S, Clarisse D, Baele F, Franceus J, Desmet T, De Bosscher K, D'hooghe M . Identification of mercaptoacetamide-based HDAC6 inhibitors via a lean inhibitor strategy: screening, synthesis, and biological evaluation . Chemical Communications . 58 . 42 . 6239–6242 . May 2022 . 35510683 . 10.1039/D2CC01550A . 248527466 . 1854/LU-8752799 . free .
29. Mwakwari SC, Patil V, Guerrant W, Oyelere AK . Macrocyclic histone deacetylase inhibitors . Current Topics in Medicinal Chemistry . 10 . 14 . 1423–1440 . 2010 . 20536416 . 3144151 . 10.2174/156802610792232079 .
30. Miller TA, Witter DJ, Belvedere S . Histone deacetylase inhibitors . Journal of Medicinal Chemistry . 46 . 24 . 5097–5116 . November 2003 . 14613312 . 10.1021/jm0303094 .
31. Monneret C . Histone deacetylase inhibitors for epigenetic therapy of cancer . Anti-Cancer Drugs . 18 . 4 . 363–370 . April 2007 . 17351388 . 10.1097/CAD.0b013e328012a5db . 39017666 .
32. http://www.clinicaltrials.gov/ct2/show/NCT00576290?term=HDAC&rank=8 Depletion of Latent HIV in CD4 Cells - Full Text View - ClinicalTrials.gov
33. Batty N, Malouf GG, Issa JP . Histone deacetylase inhibitors as anti-neoplastic agents . Cancer Letters . 280 . 2 . 192–200 . August 2009 . 19345475 . 10.1016/j.canlet.2009.03.013 .
34. Patil V, Sodji QH, Kornacki JR, Mrksich M, Oyelere AK . 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition . Journal of Medicinal Chemistry . 56 . 9 . 3492–3506 . May 2013 . 23547652 . 3657749 . 10.1021/jm301769u .
35. Mwakwari SC, Guerrant W, Patil V, Khan SI, Tekwani BL, Gurard-Levin ZA, Mrksich M, Oyelere AK . 6 . Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton . Journal of Medicinal Chemistry . 53 . 16 . 6100–6111 . August 2010 . 20669972 . 2924451 . 10.1021/jm100507q .
36. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP . Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A . Journal of the American Chemical Society . 132 . 31 . 10842–10846 . August 2010 . 20614936 . 2916045 . 10.1021/ja102758v .
37. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC . Clinical development of histone deacetylase inhibitors as anticancer agents . Annual Review of Pharmacology and Toxicology . 45 . 495–528 . 2005 . 15822187 . 10.1146/annurev.pharmtox.45.120403.095825 .
38. Yang XJ, Seto E . HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention . Oncogene . 26 . 37 . 5310–5318 . August 2007 . 17694074 . 10.1038/sj.onc.1210599 . free .
39. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV, de Cabo R, Ulrich S, Akassoglou K, Verdin E . 6 . Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor . Science . 339 . 6116 . 211–214 . January 2013 . 23223453 . 3735349 . 10.1126/science.1227166 . 2013Sci...339..211S .
40. Arbuckle JH, Medveczky PG . The molecular biology of human herpesvirus-6 latency and telomere integration . Microbes and Infection . 13 . 8–9 . 731–741 . August 2011 . 21458587 . 3130849 . 10.1016/j.micinf.2011.03.006 .
41. Beus M, Rajić Z, Maysinger D, Mlinarić Z, Antunović M, Marijanović I, Fontinha D, Prudêncio M, Held J, Olgen S, Zorc B . 6 . SAHAquines, Novel Hybrids Based on SAHA and Primaquine Motifs, as Potential Cytostatic and Antiplasmodial Agents . ChemistryOpen . 7 . 8 . 624–638 . August 2018 . 30151334 . 6104433 . 10.1002/open.201800117 .